We are excited to share the Essential1 topline data with the essential tremor (ET) community: Results show potential for ulixacaltamide (previously PRAX-944) to transform the treatment of essential tremor (ET). At Praxis, we understand that ET is more than tremor and that it can have a deep and far-reaching impact on the lives of people living with the condition as well as their care partners and communities.
See results to the Essential1 Study below
Please sign up below to receive communications from Praxis Precision Medicines about essential tremor and clinical trial updates.
We use cookies to improve your experience and to help us understand how you use our site. Please refer to our cookie notice and privacy statement for more information regarding cookies and other third-party tracking that may be enabled.
For more information on Praxis, including our privacy policy, visit us at https://praxismedicines.com
If you have any questions, please email us at praxismovement@praxismedicines.com
© 2022 Praxis Precision Medicines, Inc.
